Sébastien Guillaume

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith, Marion Procter, Richard D. Gelber et al. · The Lancet · 2007 · 1.5K citations

Medicine, Oncology, Breast Oncology +15

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Martine Piccart, Marion Procter, Debora Fumagalli et al. · Journal of Clinical Oncology · 2021 · 359 citations · Full text

Medicine, Oncology, Pharmacology +17

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials

Matteo Lambertini, Samuel Martel, Christine Campbell et al. · Cancer · 2018 · 72 citations · Full text

Medicine, Obstetrics, Oncology +17

Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer

Martine Piccart, Marion Procter, Debora Fumagalli et al. · Cancer Research · 2020 · 34 citations

Medicine, Oncology, Pharmacology +17

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

Alvaro Moreno‐Aspitia, Eileen Holmes, Christian Jackisch et al. · European Journal of Cancer · 2021 · 28 citations · Full text

Pharmacy, Translational Sciences, Translational Medicine +9